Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Regorafenib is an oral multi-kinase inhibitor used as salvage therapy for metastatic colorectal cancer (mCRC). We tested whether serum cytokine levels are associated with clinical outcome in the mCRC patients receiving regorafenib. Serum samples were collected before treatment start, day 21, and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Wakatsuki, Takeru, Horiike, Yuki, Matsusaka, Satoshi, Dan, Shingo, Shinozaki, Eiji, Seimiya, Hiroyuki, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Yamaguchi, Toshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085191/
https://www.ncbi.nlm.nih.gov/pubmed/27166185
http://dx.doi.org/10.18632/oncotarget.9187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085191/
https://www.ncbi.nlm.nih.gov/pubmed/27166185
http://dx.doi.org/10.18632/oncotarget.9187

Ejemplares similares